MedTrace Logo

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

NCT03795272 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-11-01

No results posted yet for this study

Summary

To evaluate the efficacy of PARP inhibitor, rucaparib as maintenance therapy for locally advanced cervical cancer

Conditions

Interventions

DRUG

Rucaparib

2:1 randomization to receive rucaparib/placebo twice daily for 24 month

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Institute of Cancer Research, United Kingdom

    collaborator OTHER

  • Central and Eastern European Oncology Group

    collaborator OTHER

  • North Eastern German Society of Gynaecological Oncology

    collaborator OTHER

  • Belgian Gynaecological Oncology Group

    collaborator OTHER

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • PGOG (Polish Gynaecologic Oncology Group)

    collaborator UNKNOWN

  • GSO Global Clinical Research BV

    collaborator OTHER

  • GCP-enhederne

    collaborator UNKNOWN

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2019-10-10
Completion
2019-10-10

Countries

  • Denmark

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03795272 on ClinicalTrials.gov